Debiopharm Innovation Fund

Debiopharm Innovation Fund invests in digital health and smart data start-ups with the aim to improve patient outcomes and quality of life, particularly in oncology and infectious diseases. They seek to establish tomorrow's standard of care by enabling innovation in drug development, drug manufacturing, and digital health. The fund focuses on companies applying AI and data-driven insights to accelerate clinical trials, improve patient outcomes, and enhance drug discovery. They aim to leverage new imaging digital biomarkers from longitudinal images to help Debiopharm accelerate time to market and improve success rates of clinical trials, and are exploring digital twins for use in virtual control arms. The fund invests in areas that can significantly reduce the time and costs of clinical trials, more accurately predict patient outcomes, or enhance drug discovery using AI and data analytics. They are interested in platforms that can acquire imaging data from trial sites and generate clinically meaningful predictions from imaging data. Additionally, they seek opportunities in areas like collaborative software platforms for expanded access to medicines, cancer data aggregation and analytics platforms for precision oncology, and privacy-preserving data collaboration platforms. Debiopharm's investment strategy is driven by a desire to positively contribute to society and the environment through corporate responsibility. The fund supports projects and works that aim at improving the quality of life for patients. They actively seek out entrepreneurs with ambitions to take their professional endeavors to the next level and provide funding and support to help them achieve their goals. They appear to be interested in solutions related to in-vivo study design, AI-driven data cleaning, precision medicine in radiology, AI for clinical teams and multimodal AI models for histology images.

Digital Health, AI, Data Analytics, Oncology, Infectious Diseases, Drug Development, Clinical Trials, Precision Medicine, AI-driven Drug Discovery

Core thematic spaces, technologies, and target market segments of interest.